Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a.
It was an interesting news day and biotechs even participated in the market strength today, which has not happened in a little while. I would not call the biotech action.
Obviously the big news of the day was the failure of drisapersen in their phase III trial and what it means for etperlirsen and SRPT. While it is not clear.
Not a lot of stock specific news but some interesting larger biotech developments. The market held up better than I thought given yesterday’s close and biotechs seemed like slight underperformers.